Abstract:The ongoing pandemic coronavirus disease COVID-19 is caused by the highly contagious single-stranded RNA virus, SARS-coronavirus 2 (SARS-CoV-2), which has a high rate of evolution like other RNA viruses. The first genome sequences of SARS-CoV-2 were available in early 2020. Subsequent whole-genome sequencing revealed that the virus had accumulated several mutations in genes associated with viral replication and pathogenesis. These variants showed enhanced transmissibility and infectivity. Soon after the first outbreak due to the wild-type strain in December 2019, a genetic variant D614G emerged in late January to early February 2020 and became the dominant genotype worldwide. Thereafter, several variants emerged, which were found to harbor mutations in essential viral genes encoding proteins that could act as drug and vaccine targets. Numerous vaccines have been successfully developed to assuage the burden of COVID-19. These have different rates of efficacy, including, although rarely, a number of vaccinated individuals exhibiting side effects like thrombosis. However, the recent emergence of the Britain strain with 70% more transmissibility and South African variants with higher resistance to vaccines at a time when several countries have approved these for mass immunization has raised tremendous concern regarding the long-lasting impact of currently available prophylaxis. Apart from studies addressing the pathophysiology, pathogenesis, and therapeutic targets of SARS-CoV-2, analysis of the gut, oral, nasopharyngeal, and lung microbiome dysbiosis has also been undertaken to find a link between the microbiome and the pathogenesis of COVID-19. Therefore, in the current scenario of skepticism regarding vaccine efficacy and challenges over the direct effects of currently available drugs looming large, investigation of alternative therapeutic avenues based on the microbiome can be a rewarding finding. This review presents the currently available understanding of microbiome dysbiosis and its association with cause and consequence of COVID-19. Taking cues from other inflammatory diseases, we propose a hypothesis of how the microbiome may be influencing homeostasis, pro-inflammatory condition, and the onset of inflammation. This accentuates the importance of a healthy microbiome as a protective element to prevent the onset of COVID-19. Finally, the review attempts to identify areas where the application of microbiome research can help in reducing the burden of the disease.

Microbiota and Its Impact on the Immune System in COVID-19—A Narrative Review

Diet, Probiotics and Their Impact on the Gut Microbiota during the COVID-19 Pandemic

Gut Microbiota and COVID-19: Potential Implications for Disease Severity

COVID-19 and Gut Microbiota: A Potential Connection

Impact of SARS-CoV2 infection on gut microbiota dysbiosis

Modulated Gut Microbiota for Potential COVID-19 Prevention and Treatment

Alterations in microbiota of patients with COVID-19: potential mechanisms and therapeutic interventions

The relationship between gut microbiota and COVID-19 progression: new insights into immunopathogenesis and treatment

Gut Microbiome Disruption Following SARS-CoV-2: A Review

Considerations for Gut Microbiota and Probiotics in Patients with Diabetes Amidst the Covid-19 Pandemic: A Narrative Review

Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications

Review Article: Probiotics, Prebiotics and Dietary Approaches During COVID-19 Pandemic

Gut Microbiome Alterations in COVID-19

COVID-19 influenced gut dysbiosis, post-acute sequelae, immune regulation, and therapeutic regimens

Potential Associations Between Microbiome and COVID-19

Decoding the bidirectional relationship between gut microbiota and COVID-19

Role of the Microbiome in the Pathogenesis of COVID-19

Short-chain fatty acids-microbiota crosstalk in the coronavirus disease (COVID-19)

Role of Gut Microbiome in COVID-19: An Insight Into Pathogenesis and Therapeutic Potential

Main Clinical Features of COVID-19 and Potential Prognostic and Therapeutic Value of the Microbiota in SARS-CoV-2 Infections

The effect of microbiome therapy on COVID-19-induced gut dysbiosis: A narrative and systematic review